SOLV Stock Analysis — Solventum
Sector: Healthcare
AI Verdict
Solventum trades at 11.7x next year's earnings while analysts expect -20.2% EPS growth, so the low multiple reflects real concerns about shrinking profits despite a defensible healthcare supply moat.
Competitive Moat
Solventum manufactures specialized healthcare products and consumables used in hospitals and clinics, benefiting from high switching costs and regulatory hurdles that make it difficult for customers to change suppliers. Its defensibility comes from embedded relationships with healthcare providers and a broad portfolio that integrates into clinical workflows.
Summary
Solventum is notable for trading at just 11.7x next year's earnings, well below the healthcare sector median of 22x.
Where It Stands
With a 1-year return of 1.60%, RSI at 48.1 (neutral), and a forward P/E of 11.7x versus the sector median of 22x, the stock is priced cheaply but with muted momentum.
Key Metrics
- RSI: 48.1 — Neutral
- Trailing P/E: 9.3x
- Forward P/E: 11.7x
- Earnings Growth: -0.2%
- Revenue Growth: -0.0%
- Market Cap: $13.2B
- 1-Year Return: 1.60%
- 52-Week High: $88.20
- 52-Week Low: $62.38
Analyst Consensus
12 Buy · 8 Hold · 2 Sell (22 analysts)
Bull Case
The forward P/E of 11.7x is nearly half the healthcare sector median, suggesting the market is pricing in a lot of bad news already.
Bear Case
With forward EPS expected to shrink by -20.2%, even a modest P/E re-rating to the sector median would require a sharp turnaround in earnings expectations.
Catalyst to Watch
Watch for quarterly earnings updates—any sign of stabilizing or improving EPS versus the current -20.2% forecast could spark a re-rating.